Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American .
Provectus Biopharmaceuticals Inc.April 28, 2021 GMT Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT0269367 ) Systemic administration of PV-10 for treatment of solid tumor cancers
KNOXVILLE, TN, April 28, 2021 (GLOBE NEWSWIRE) Provectus (OTCQB: PVCT) today announced that two abstracts about data from clinical and preclinical study of investigational cancer immunotherapy PV-10 (rose bengal disodium) were accepted for the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, which will be held June 4-8 online.